Sign In
Buy NRXP
$4.05
-0.570 (-12.34%)
At Close: Jun 03, 2026
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
08:59am, Monday, 03'rd Feb 2025
HOPE has announced plans to assemble a best-in-class global network of interventional psychiatry clinics combining ketamine treatment with transcranial magnetic stimulation, and digital therapeutics t
$25 million investment in HOPE to consist of Series A (non-dilutive to NRx shareholders) convertible into 1/3 of fully diluted HOPE equity, with a 15% current preferred dividend (non-callable for 2 ye
This financing is expected to support filing of New Drug Applications for NRX-100 (ketamine) and NRX-101, and to support launch of HOPE Therapeutics Investment consists of $3.5 million in above the m
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement
08:02am, Tuesday, 21'st Jan 2025
Company received written notice from the Nasdaq Listing Qualifications Staff stating that the Company regained compliance with the applicable Nasdaq minimum market value of listed securities continued
WILMINGTON, Del. , Jan. 15, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc
"'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay Gupta David Feifel MD PHD, Founder of Kadima, is a global thought leader in the interventional psychiatry field Kadima Neur
Management believes uplisting has the potential to provide shareholders with improved liquidity Requires NRx Pharmaceuticals to meet certain listing requirements Company has advised NASDAQ that curren
Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region
10:20am, Wednesday, 08'th Jan 2025
Pfizer, Johnson & Johnson (Janssen Pharmaceuticals), Roche Holding, Novartis, and Eli Lilly & Company Dominate the Competitive Landscape Pfizer, Johnson & Johnson (Janssen Pharmaceuticals), Roche Hold
The Keynote Address, entitled " Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD ," will be presented at 10:30AM PT on Sunday January 12th, 2025 Prof. David Feifel M
Best Momentum Stocks to Buy for January 6th
11:35am, Monday, 06'th Jan 2025
NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024.
Anticipated c apital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRx Pharmaceutical operations. Purchase of $25 m i
Dura Medical, with initial clinics in Naples and Fort Myers, to anchor the HOPE network in Florida Delivers a full range of precision psychiatry services, including Ketamine and Transcranial Magnetic
New Strong Buy Stocks for January 6th
05:25am, Monday, 06'th Jan 2025
ALK, AHT, NRXP, PDEX and EGAN have been added to the Zacks Rank #1 (Strong Buy) List on January 6, 2024.
Kadima Neuropsychiatry Institute in La Jolla, CA to serve as flagship for an international network of clinics dedicated to treating depression and PTSD Kadima's founder, David Feifel, MD, PhD, Profess
Best Momentum Stocks to Buy for December 30th
11:01am, Monday, 30'th Dec 2024
CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024.
